The U.S. Food and Drug Administration said on Monday that it had launched a generative AI tool, Elsa, aimed at improving efficiency across its operations, including scientific reviews.
“Today’s rollout of Elsa is ahead of schedule and under budget, thanks to the collaboration of our in-house experts across the centers,” said FDA Commissioner Marty Makary.
The agency said it is already using Elsa to expedite clinical protocol reviews, shorten the time needed for scientific evaluations, and pinpoint high-priority inspection targets.
Once the FDA receives an application for a potential drug approval, it has six to 10 months to make a decision.
Elsa assists with reading, writing, and summarizing tasks. It can summarize adverse events to support safety profile assessments of drugs and rapidly compare packaging inserts.
“Elsa offers a secure platform for FDA employees to access internal documents while ensuring all information remains within the agency. The models do not train on data submitted by regulated industry, safeguarding the sensitive research and data handled by FDA staff,” the FDA said.
In May, the regulator said it would fully integrate AI by June 30, following an experimental run.
—Puyaan Singh, Reuters
Melden Sie sich an, um einen Kommentar hinzuzufügen
Andere Beiträge in dieser Gruppe
Fraudulent job applications have become a serious issue in the era of
With the first family actively engaged in memecoin ventures, speculation about the future of cryptocurrency has never been hotter. Laura Shin, crypto expert and host of the podcast Unchained
When Mike Krieger helped launch Instagram in 2010 as a cofounder, building something as simple as a photo filter took his team wee
“Fuck around” and “find out,” read a TikTok post that followed a screenshot announcing that California is suing President Donald Trump for deploying
It’s 2009. Everyone is rocking ankle socks. “TikTok,” is just a Ke$ha song. You pull out your BlackBerry Bold 9700 and update your BlackBerry Messenger (BBM) status. All is well.
Before
Voyager Technologies raised $382.8 million in its U.S. initial public offering, the space and defense tech company said on Tuesday, amid a
